Anamorelin Effectively Targets Cachexia in Patients with Advanced Non Small Cell Lung Cancer

Patients with some cancers, such as pancreatic and especially non small cell lung cancer- the most common cancer killer frequently waste away not attributable to chemotherapy but various factors tumors produce- killing appetite and so much more metabolically and psychologically. There are some treatments  to try and stimulate appetite but they are not that effective or can be not worth it and in essence do not go after the mechanism of this cachexia, as it called. Patients who waste away have shorter remissions , less responses and shorter survival and is not due to a mere lack of effort on their part, this breakthrough study shows the utility of another drug

Treatment with anamorelin, a highly selective ghrelin receptor agonist, resulted in significant increases in lean body mass and body weight in patients with advanced non–small cell lung cancer (NSCLC) and cachexia compared with placebo, according to the results of the ROMANA 1 and 2 trials presented during the Patient and Survivor Care Oral Abstract Session on Monday, June 1

Advertisements

One thought on “Anamorelin Effectively Targets Cachexia in Patients with Advanced Non Small Cell Lung Cancer

  1. drkevinryan Post author

    So sorry to hear you feel this way. You are, with all due respect, woefully misinformed. There is no harm to read solid facts from the other side- get the book. There is NO CORROBORATED DATA OR TRIAL CORRRECTLY DOEN that shows what you assert- none, sorry

    Like

    Reply

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s